BIO CEO and Investor Conference in New York on February 14, 2012, 9:00 a.m. ET; and Leerink Swann Global Healthcare Conference in New York on February 15, 2012, 4:00 p.m. ET.A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at www.transcept.com. The archive of the presentation will be available there for approximately 30 days following the event. About Transcept Pharmaceuticals Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Transcept and Purdue are parties to a collaboration agreement for the development and commercialization of Intermezzo in the United States. Transcept holds all commercialization and development rights to Intermezzo outside North America and has co-promotion rights to Intermezzo in the United States. As part of its product pipeline activities, Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For information about Intermezzo, please visit www.intermezzorx.com. For further information about Transcept, please visit www.transcept.com. Contact:Transcept Pharmaceuticals, Inc. Greg MannDirector, Corporate Communications(510) 215-3567 email@example.com SOURCE Transcept Pharmaceuticals, Inc.